High stakes for Swiss pharmaceutical industry in EU negotiations
The Swiss life sciences industry accounts for nearly half of Swiss exports.
Keystone / Yannick Bailly
Switzerland risks losing out as a production location if differences with the European Union (EU) are not resolved, says president of Novartis Switzerland, Matthias Leuenberger.
This content was published on
2 minutes
Keystone-SDA/jdp
Italiano
it
Alta posta in gioco per l’industria farmaceutica svizzera nei negoziati con l’UE
In an interviewExternal link in the Neue Zürcher Zeitung, Leuenberger said he was encouraged by the Swiss government announcement last week about a new strategy for stabilising relations with the EU.
“There is a lot at stake for our industry. Switzerland and especially the Basel area have always been of great importance to us in research, development and production,” said the Novartis Switzerland president. “In order for things to stay that way, we need regulated relations with the EU – in exports, in research and in the recruitment of specialists.”
While pharmaceutical exports to the US and China have increased, Europe remains an important destination for around 48% of the industry exports.
The mutual recognition agreement between the EU and Switzerland on pharmaceutical products is expected to expire in a few years. If it isn’t renewed, Switzerland as a production location would suffer because companies would need to conduct multiple checks and inspections that aren’t required today. Leuenberger estimates the additional costs for the entire pharmaceutical industry would amount to CHF500 million ($558 million) a year.
He argued the consequences of this won’t be felt immediately but will gradually erode the country’s attractiveness.
“Many companies have come to Switzerland in recent years, established themselves here and invested in new plants. They depend on the framework conditions not deteriorating,” said Leuenberger.
The life sciences industry accounts for almost half of all Swiss exports – over CHF134 billion. Around 90% of what is produced in Switzerland is exported.
Talks on an overarching framework treaty with the EU to oversee long-term ties between Brussels and Bern broke down in 2021 when Switzerland walked away from the negotiating table.
The two parties have held a series of exploratory talks in an attempt to revive official negotiations. On June 21, the Swiss government announced foundational principles as part of a new strategy to stabilise relations with the EU.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
This content was published on
Switzerland announces new strategy for stabilising relations with the EU, which have hit a rocky patch in the last two years.
Swiss research chief sounds alarm over Horizon Europe exclusion
This content was published on
The Swiss research chief has warned of the negative impact of Switzerland's continued exclusion from the EU's Horizon programme.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.